Nonpenetrating glaucoma surgery cannot achieve lower target IOP

Article

Nonpenetrating glaucoma surgery has little potential to reduce intraocular pressure (IOP) values, according to a study published in the March issue of the Journal of Ophthalmology.

Nonpenetrating glaucoma surgery has little potential to reduce intraocular pressure (IOP) values, according to a study published in the March issue of the Journal of Glaucoma.

Ahmet Hondur, MD of Dinar State Hospital, Turkey and colleagues assessed the impact of nonpenetrating surgery on IOP by reviewing studies on nonpenetrating glaucoma surgery, deep sclerectomy (DS) and viscocanalostomy (VC) (excluding those reporting on combined glaucoma and cataract surgery) from the past five years.

Following primary DS, DS with implant, DS with antimetabolite, primary VC and VC with implant or antimetabolite, cases achieving IOP of ≤21 mmHg were 48.6%, 68.7%, 67.1%, 51.1% and 36.8%, respectively. The research team determined effectiveness in terms of target IOP achievement. For lower set IOP targets, DS and VC success rates were 35 – 86% and 10 – 67%, respectively.

Based on these data, the team concluded that the potential of nonpenetrating surgery to achieve lower target IOPs is low, although this type of surgery can reduce IOP into the high teens.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.